의사-제약회사 상호관계가 연구에 미치는 영향

키워드

참고문헌 (39)

1. Angell M, "Industry-sponsored clinical research: a broken system", JAMA, 300, pp.1069~1071 (2008)
2. Bekelman JE, "Scope and impact of financial conflicts of interest in biomedical research: a systematic review", JAMA, 289, pp.454~465 (2003)
3. Bernard Lo, "Committee on Conflict of Interest in Medical Research, Education, and Practice; Institute of Medicine, Conflict of Interest in Medical Research, Education, and Practice" (2009), The National Academies Press
4. Bourgeois FT, "Outcome reporting among drug trials registered in ClinicalTrials.gov", Ann Intern Med, 153, pp.158~166 (2010)
5. Bruce MP, "COX-2 inhibitors - lessons in drug safety", N Engl J Med, 352, pp.1133~1135 (2005)
6. DeAngelis CD, "Ensuring integrity in industry-sponsored research. Primum non nocere, revisited", JAMA, 303, pp.1196~1198 (2010)
7. DeAngelis CD, "Impugning the integrity of medical science: the adverse effects of industry influence", JAMA, 299(15), pp.1833~1835 (2008)
8. Department of Health and Human Services, USA, "Office of Inspector General, The Globalization of Clinical Trials A Growing Challenge in Protecting Human Subjects. 2001 OEI-01-00-00190", ~ (2001)
9. Doucet M, "Evaluating solutions to sponsorship bias", J Med Ethics, 34, pp.627~630 (2008)
10. Drazen JM, "Institutions, contracts, and academic freedom", N Engl J Med, 347, pp.1362~1363 (2002)
11. Dunn C, "Protecting study volunteers in research", Thomson Center Watch, pp.141~149 (2002)
12. Dyer O, "GlaxoSmithKline faces US lawsuit over concealment of trial results", BMJ, 328(7453), pp.1395~ (2004)
13. Dyer O, "GlaxoSmithKline to set up comprehensive online clinical trials register", BMJ, 329(7466), pp.590~ (2004)
14. Bombardier, "Comparison of upper gastrointestinal toxicity of Rofecoxib and Naproxen in patients with rheumatoid arthritis", N Engl J Med, 343, pp.1520~1528 (2000)
15. Fontanarosa PB, "Reporting conflicts of interest, financial aspects of research, and role of sponsors in funded studies", Journal of American Medical Association, 294, pp.110~111 (2005)
16. Gottlieb S, "Researchers deny any attempt to mislead the public over JAMA article on arthritis drug", BMJ, 323, pp.301~ (2001)
17. Hampson LA, "Empirical Data on Conflicts of Interest, in The Oxford Textbook of Clinical Research Ethics", pp.767~779 (2008), Oxford University Press
18. Hrachovec JB, "Letter: Reporting of 6-month vs 12-month data in a clinical trial of celecoxib", JAMA, 286, pp.2398~ (2001)
23. Juni P, "Risk of cardiovascular events and rofecoxib: cumulative meta-analysis", The Lancet, 364, pp.2021~2029 (2004)
24. Kondro W, "Drug company experts advised staff to withhold data about SSRI use in children", CMAJ, 170(5), pp.783~ (2004)
25. Liebson P, "The thiazolidinedione controversy in cardiovascular risk", Preventive Cardiology, 13(4), pp.209~212 (2010)
26. Matcham J, "Proposed best practice for statisticians in the reporting and publication of pharmaceutical industry-sponsored clinical trials", Pharmaceut Statist, 10, pp.70~73 (2011)
27. Melander H, "Evidence b(i)ased medicine-selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications", BMJ, 326, pp.1711~ (2003)
28. Miller FG, "Ethical assessment of industry-sponsored clinical trials: a case analysis", Chest, 121, pp.1337~1342 (2002)
29. Psaty BM, "Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: a case study based on documents from rofecoxib litigation", JAMA, 299(15), pp.1813~1817 (2008)
30. Pyke S, "The potential for bias in reporting of industry-sponsored clinical trials", Pharmaceut Statist, 10, pp.74~79 (2011)
31. Rennie D, "Thyroid storm", JAMA, 277, pp.1238~1243 (1997)
32. Wise J, "Research suppressed for seven years by drug company", BMJ, 314, pp.1145~ (1997)
33. Ross JS, "Guest authorship and ghost writing in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation", JAMA, 299(15), pp.1800~1812 (2008)
34. Silverstein FE, "Letter: Reporting of 6-month vs 12-month data in a clinical trial of celecoxib", JAMA, 286, pp.2399~ (2001)
35. Song F, "Dissemination and publication of research findings: an updated review of related biases", Health Technology Assessment, 14, pp.1~220 (2010)
36. Steinbrook R, "Gag clauses in clinical-trial agreements", The New England Journal of Medicine, 352, pp.2160~2162 (2005)
37. Whittington DJ, "Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data", Lancet, 363, pp.1341~1345 (2004)
38. Wright JM, "Letter: Reporting of 6-month vs 12-month data in a clinical trial of celecoxib", JAMA, 286, pp.2398~2399 (2001)
39. Wynia M, "Better regulation of industry-sponsored clinical trials is long overdue. The Journal of Law", Medicine & Ethics, 37(3), pp.395~419 (2009)

관련 논문AI추천